Cliff Asness's PCRX Position Overview
Cliff Asness (via Aqr Capital Management LLC) currently holds 154,298 shares of Pacira BioSciences, Inc. (PCRX) worth $3.49 M, representing 0.00% of the portfolio. First purchased in 2012-Q4, this long-term strategic position has been held for 39 quarters.
Based on 13F filings, Cliff Asness has maintained a strategic position in PCRX, demonstrating sustained confidence in this investment. Largest addition occurred in Q3 2024, adding 478,595 shares. Largest reduction occurred in Q4 2024, reducing 257,709 shares.
Analysis based on 13F filings available since 2013 Q2
Cliff Asness's Pacira BioSciences (PCRX) Holding Value Over Time
Track share changes against reported price movement
Quarterly Pacira BioSciences (PCRX) Trades by Cliff Asness
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | +17,065 | Add 12.44% | 154,298 | $22.60 |
| Q4 2025 | -3,168 | Reduce 2.26% | 137,233 | $25.88 |
| Q3 2025 | -1,762 | Reduce 1.24% | 140,401 | $25.77 |
| Q2 2025 | -34,620 | Reduce 19.58% | 142,163 | $23.90 |
| Q1 2025 | -111,716 | Reduce 38.72% | 176,783 | $24.85 |
| Q4 2024 | -257,709 | Reduce 47.18% | 288,499 | $18.84 |
| Q3 2024 | +478,595 | Add 707.84% | 546,208 | $15.05 |
| Q2 2024 | +5,918 | Add 9.59% | 67,613 | $28.61 |
| Q1 2024 | -81,079 | Reduce 56.79% | 61,695 | $29.22 |
| Q4 2023 | +33,953 | Add 31.20% | 142,774 | $33.74 |
| Q3 2023 | +68,061 | Add 166.98% | 108,821 | $30.68 |
| Q2 2023 | +11,696 | Add 40.24% | 40,760 | $40.07 |
| Q1 2023 | +29,064 | New Buy | 29,064 | $40.81 |
| Q2 2021 | -7,867 | Sold Out | 0 | $0.00 |
| Q1 2021 | -7,877 | Reduce 50.03% | 7,867 | $70.04 |
| Q4 2020 | -2,975 | Reduce 15.89% | 15,744 | $59.83 |
| Q3 2020 | -31,197 | Reduce 62.50% | 18,719 | $60.10 |
| Q2 2020 | -3,295 | Reduce 6.19% | 49,916 | $52.47 |
| Q1 2020 | +23,685 | Add 80.22% | 53,211 | $33.53 |
| Q4 2019 | -91,263 | Reduce 75.56% | 29,526 | $45.32 |
| Q3 2019 | -16,652 | Reduce 12.12% | 120,789 | $38.07 |
| Q2 2019 | -13,771 | Reduce 9.11% | 137,441 | $43.49 |
| Q1 2019 | +73,862 | Add 95.49% | 151,212 | $38.06 |
| Q4 2018 | +72,259 | Add 1419.35% | 77,350 | $43.03 |
| Q3 2018 | -20,143 | Reduce 79.82% | 5,091 | $49.11 |
| Q2 2018 | -64,594 | Reduce 71.91% | 25,234 | $32.06 |
| Q1 2018 | +89,828 | New Buy | 89,828 | $31.15 |
| Q3 2015 | -10,703 | Sold Out | 0 | $0.00 |
| Q2 2015 | -818 | Reduce 7.10% | 10,703 | $70.73 |
| Q1 2015 | -5,886 | Reduce 33.81% | 11,521 | $88.88 |
| Q4 2014 | -41,994 | Reduce 70.70% | 17,407 | $88.64 |
| Q3 2014 | +44,900 | Add 309.63% | 59,401 | $96.92 |
| Q2 2014 | -2,400 | Reduce 14.20% | 14,501 | $91.86 |
| Q1 2014 | -18,900 | Reduce 52.79% | 16,901 | $70.00 |
| Q4 2013 | -2,506 | Reduce 6.54% | 35,801 | $57.48 |
| Q3 2013 | -3,708 | Reduce 8.83% | 38,307 | $48.09 |
| Q2 2013 | +42,015 | Add 0.00% | 42,015 | $28.99 |
| Q4 2012 | +35,352 | Add 0.00% | 35,352 | $17.48 |
Cliff Asness's Pacira BioSciences Investment FAQs
Cliff Asness first purchased Pacira BioSciences, Inc. (PCRX) in Q4 2012, acquiring 35,352 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Cliff Asness has held Pacira BioSciences, Inc. (PCRX) for 39 quarters since Q4 2012.
Cliff Asness's largest addition to Pacira BioSciences, Inc. (PCRX) was in Q3 2024, adding 546,208 shares worth $8.22 M.
According to the latest 13F filing for Q1 2026, Cliff Asness's firm, Aqr Capital Management LLC, owns 154,298 shares of Pacira BioSciences, Inc. (PCRX), valued at approximately $3.49 M.
As of the Q1 2026 filing, Pacira BioSciences, Inc. (PCRX) represents approximately 0.00% of Cliff Asness's publicly disclosed stock portfolio, making it one of their key holdings.
Cliff Asness's peak holding in Pacira BioSciences, Inc. (PCRX) was 546,208 shares, as reported at the end of Q3 2024.